FDA Strengthens Safety Label Warnings for Fluoroquinolone Antibiotics
The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
Related News Articles
Headline
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system…
Headline
In this conversation, Oren Guttman, M.D., anesthesiologist and vice president of High Reliability & Patient Safety at Thomas Jefferson University,…
Headline
A new AHA case study highlights how Springfield Memorial Hospital in Illinois revised its patient safety culture through the implementation of its unique,…
Chairperson's File
In this episode, I talk with Steve Diaz, M.D., chief medical officer at MaineGeneral Health in Augusta and an AHA board member. Steve is an emergency medicine…
Headline
The AHA Sept. 26 launched a new video series in which former AHA Board Chair Mindy Estes, M.D., has conversations with hospital and health system leaders about…
Perspective
There will always be administrative costs associated with operating a hospital. But the lion’s share of a hospital’s resources should be devoted to doing what…